Key investor takeaways from bioMerieux 2025 earnings call:
- Strong top-line and profitability: bioMerieux reached a milestone of ~€4.0 billion in sales for 2025, with 6.2% organic growth (7.8% ex-China). Contributive EBIT (CEBIT) grew ~16% organically and the reported CEBIT margin reached 17.9%. Adjusted net income / adjusted EPS rose ~9% and the Board will propose a €0.98/share dividend (up 9%).
- Excellent cash generation and balance sheet: Free cash flow was ~€460 million (up ~40% vs 2024). Net cash position ended positive at ~€108 million after 2025 acquisitions.
- Commercial momentum and product rollouts: BIOFIRE installed base grew by ~1,800 net units in 2025 (installed base ~28,500). SPOTFIRE placements rose sharply (+110% year, ~6,400 instruments in 2025, with ~900 in Q4), and the company is scaling point-of-care offerings (nasal swab, upcoming low-plex CE panel for Europe). Microbiology (33% of sales) showed instrument growth (≈14%) but was impacted by China (China down ~14% in 2025). Industrial/Pharma applications and pharma-related launches (e.g., Accellix acquisition) are strong drivers.
- 2026 guidance and roadmap: Group sales guidance +5% to +7% (around +6% midpoint) and at least +10% organic CEBIT growth. Key product near-term launches include SpinChip (CE filing progress), SPOTFIRE vaginitis panel (filed in 2026 target), and additional SPOTFIRE low-plex EU options. SPOTFIRE sales expected to grow 40%–60% in 2026 on the path to the 2028 ambition.
- Risks / headwinds: China market weakness remains (guidance assumes a mid-single-digit decline in China in 2026). Significant currency/FX headwind: management currently estimates a ~€50–60 million negative impact on CEBIT from FX at current rates. U.S. tariffs and procurement/tariff pressures also weighed on margins (tariff impact expected to be material in 2026 versus 2025).
- Operational efficiency & CSR: GO.28 transformation is delivering (gross margin improvement, procurement/supply-chain savings, automation of pouch manufacturing ~40% automated). Management upgraded CSR ambitions (adding Scope 3 target, Net Zero by 2050) after a ~29% absolute GHG reduction vs 2019 while growing sales ~50% since 2019.
- M&A and capital allocation: continued focus on bolt-on acquisitions that extend core franchises (Accellix added for pharma QC; SpinChip acquired earlier). Management increased dividend and retains capacity for targeted acquisitions.
Overall, investors should note a combination of durable installed-base-led growth (BIOFIRE, SPOTFIRE), continued margin expansion via GO.28 efficiency actions, strong cash generation, but near-term sensitivity to respiratory seasonality, China market softness and meaningful FX/tariff headwinds.
Sign In
Buy BMXXY
